Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1

References

• Luo ZC, An N, Xu HR, et al. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol 2007;21:36–45
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565
   PubMed Web of Science ®Google Scholar
• Deis S, Rouzier R, Kayem G, et al. Development of a nomogram to predict occurrence of preeclampsia. Eur J Obstet Gynecol Reprod Biol 2007;137:146–51
   Google Scholar
• Dildy GA, 3rd Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol 2007;31:135–41
   PubMed Web of Science ®Google Scholar
• Badria LF, Amarin ZO. Pre-eclampsia: is it a different disease in primiparous and multiparous women? Arch Gynecol Obstet 2005;273:26–31
   Google Scholar
• Dukler D, Porath A, Bashiri A, et al. Remote prognosis of primiparous women with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001;96:69–74
   PubMedGoogle Scholar
• Dekker GA, Robillard PY, Hulsey TC. Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv 1998;53:377–82
   PubMedGoogle Scholar
• Mekori YA, Becker M, Moalem I, et al. Immunological features of preeclampsia: increased frequency of antilymphocyte antibodies, but not of immune complexes. Isr J Med Sci 1981;17:1051–5
   PubMedGoogle Scholar
• Barden AE, Beilin LJ, Ritchie J, et al. Is proteinuric pre-eclampsia a different disease in primigravida and multigravida? Clin Sci (Lond) 1999;97:475–83
   PubMed Web of Science ®Google Scholar
• Wolf M, Sandler L, Jimenez-Kimble R, et al. Insulin resistance but not inflammation is associated with gestational hypertension. Hypertension 2002;40:886–91
   PubMed Web of Science ®Google Scholar
• Lachmeijer AM, Dekker GA, Pals G, et al. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002;105:94–113
   PubMed Web of Science ®Google Scholar
• Mijal RS, Holzman CB, Rana S, et al. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244 e1–12
   Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856–69
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555–63
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605–8
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348–51
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541–7; discussion 1547–50
   PubMed Web of Science ®Google Scholar
• Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004;50:1702–3
   PubMed Web of Science ®Google Scholar
• Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122:478–87
   PubMed Web of Science ®Google Scholar
• Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77–85
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–19
   PubMed Web of Science ®Google Scholar
• Bdolah Y, Palomaki GE, Yaron Y, et al. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006;194:239–45
   PubMed Web of Science ®Google Scholar
• Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198:428 e1–6
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Tajima T, et al. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010;94:305–8
   Google Scholar
• Kanter D, Lindheimer MD, Wang E, et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010;202:184 e1–5
   Google Scholar
• Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198:200 e1–7
   Web of Science ®Google Scholar
• Mijal RS, Holzman CB, Rana S, et al. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244 e1–12
   Web of Science ®Google Scholar
• Faupel-Badger JM, Staff AC, Thadhani R, et al. Maternal angiogenic profile in pregnancies that remain normotensive. Eur J Obstet Gynecol Reprod Biol 2011;158:189–93
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161 e1–161 e11
   PubMed Web of Science ®Google Scholar
• Parazzini F, Bortolus R, Chatenoud L, et al. Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group. Epidemiology 1996;7:306–8
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Belizan JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. BJOG 2000;107:75–83
   PubMed Web of Science ®Google Scholar
• Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005;193:16–22
   PubMed Web of Science ®Google Scholar
• Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the “chicken-and-egg” question. Endocrinology 2004;145:4835–7
   PubMed Web of Science ®Google Scholar
• Odegard RA, Vatten LJ, Nilsen ST, et al. Risk factors and clinical manifestations of pre-eclampsia. BJOG 2000;107:1410–16
   PubMed Web of Science ®Google Scholar
• Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997;177:1003–10
   PubMed Web of Science ®Google Scholar
• Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol 2002;187:1013–18
   PubMed Web of Science ®Google Scholar